Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – FDA Approves U.S. Product Labeling Update for Sprycel® (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase

[Business Wire] – Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc. today announced that the U.S. Food and Drug Administration has approved an update to the Sprycel® product labeling. Read more on this. . . . → Read More: Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – FDA Approves U.S. Product Labeling Update for Sprycel® (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase Similar Articles: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb and The Leukemia & Lymphoma Society Announce Charitable Donation to Support Critical Routine Testing and Awareness for Chronic Myeloid Leukemia Patients Market Update (NYSE:BMY): Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen Market Update (NYSE:BMY): Bristol-Myers Squibb Announces Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding Debt Securities